Adjuvant interferon therapy in high-risk melanoma: For which patients? [Adjuvante Interferontherapie beim Hochrisikomelanom : Welche Patienten kommen in Frage?]

被引：0
|
作者：
Hauschild A. [1 ,2 ]
Kähler C. [1 ]
机构：
[1] Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Schleswig-Holstein, Kiel
[2] Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, 24105 Kiel
来源：
best practice onkologie | 2007年 / 2卷 / 2期
关键词：
D O I：
10.1007/s11654-007-0014-7
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：4 / 13
页数：9
相关论文
共 50 条
  • [41] Evaluation of IL-10 polymorphisms in high-risk melanoma patients receiving adjuvant interferon
    Gogas, H.
    Metaxas, Y.
    Polyzos, A.
    Mantzourani, M.
    Antoniadis, A.
    Floudas, C.
    Fountzilas, G.
    Pectasides, D.
    Tsoutsos, D.
    Spyropoulou-Vlachou, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] Adjuvant therapy for high-risk primary and resected metastatic melanoma
    Hersey, P
    INTERNAL MEDICINE JOURNAL, 2003, 33 (1-2) : 33 - 43
  • [43] Adjuvant Therapy in High-Risk Stage III Cutaneous Melanoma
    Barker, Christopher A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 11 - 12
  • [44] A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma
    Messori, A
    Becagli, P
    Trippoli, S
    Tendi, E
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (09) : 1373 - 1379
  • [45] Adjuvant Therapy in High-Risk, Node-Negative Melanoma
    Ross, Merrick I.
    McBride, Charles M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (08) : 445 - 448
  • [46] The feasibility of adjuvant interferon α-2b in children with high-risk melanoma
    Navid, F
    Furman, WL
    Fleming, M
    Rao, BN
    Kovach, S
    Billups, CA
    Cain, AM
    Amonette, R
    Jenkins, JJ
    Pappo, AS
    CANCER, 2005, 103 (04) : 780 - 787
  • [47] Autoantibody prevelance in high-risk melanoma patients treated with adjuvant high-dose interferon α-2a.
    Gogas, H
    Frangia, K
    Bafaloukos, D
    Polyzos, A
    Pectasides, D
    Ioannovich, I
    ANNALS OF ONCOLOGY, 2000, 11 : 127 - 127
  • [48] Cost-effectiveness of ipilimumab versus high-dose interferon as an adjuvant therapy in resected high-risk melanoma
    Salans, Mia
    Courtney, Patrick Travis
    Yip, Anthony
    Murphy, James D.
    CANCER MEDICINE, 2021, 10 (19): : 6618 - 6626
  • [49] Toxicity of combined treatment of adjuvant irradiation and interferon a2b in high-risk melanoma patients
    Conill, Carlos
    Jorcano, Sandra
    Domingo-Domenech, Josep
    Marruecos, Jordi
    Vilella, Ramon
    Malvehy, Josep
    Puig, Susana
    Sanchez, Marcelo
    Gallego, Rosa
    Castel, Teresa
    MELANOMA RESEARCH, 2007, 17 (05) : 304 - 309
  • [50] Correlation of molecular HLA typing and outcome in high-risk melanoma patients receiving adjuvant interferon.
    Gogas, H.
    Spyropoulou-Vlachou, M.
    Dafni, U.
    Tsoutsos, D.
    Markopoulos, C.
    Polyzos, A.
    Stratigos, A.
    Pectasides, D.
    Bafaloukos, D.
    Fountzilas, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 460S - 460S
12345